Array Raring To Go Commercially With First Approval – Mektovi/Braftovi

Array believes that a zero copay offer for patients will help its newly FDA-approved Mektovi/Braftovi combination stand out from the crowd in melanoma and notes that the regimen also has potential in a larger indication – colon cancer.